Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fmed.2020.606429 http://scihub22266oqcxt.onion/10.3389/fmed.2020.606429 33585508!7873594!33585508     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Med+(Lausanne) 2020 ; 7 (ä): 606429 Nephropedia Template TP {{tp|p=33585508|t=2020. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis |pdf=|usr=}}{{33585508}} gab.com Text Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis JO: Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=33585508 #FOAvip Importance/Background: During current public health emergency of COVID-19 pandemic, repurposing of existing antiviral drugs may be an efficient strategy since there is no proven effective treatment. Published literature shows Remdesivir has broad-spectrum antiviral activity against numerous RNA viruses and has been recently recognized as a promising therapy against SARS-CoV-2. Methods: A systematic search was conducted for full length manuscripts published between inception and July 19th, 2020 focussing on efficacy and safety of Remdesivir in COVID-19. The primary outcomes were defined as mortality rate and median days to recovery based on the available pooled data. The secondary outcome was adverse events rate and drug discontinuation rate. Statistical Analysis: All outcomes were performed using Comprehensive Meta-Analysis software package (Bio stat, Englewood, NJ, USA). Results: A total of 1,895 patients from 9 studies were included in this qualitative synthesis. In patients treated with Remdesivir, the mean recovery time was 15.84 days (95% CI 11.68-20, SE 2.12; I (2) = 97.24) and the pooled mortality rate was 11.3% (95% CI 7.9-16%; I (2) = 74.85). However, treatment with Remdesivir was associated with adverse effects (55.3%, 95% CI 31.5-76.9%; I (2) = 97.66) eventually warranting the discontinuation of the drug (17.8%, 95% CI 8.6-33.1%; I (2) = 95.64). The meta-analysis of three clinical trials indicated that administration of Remdesivir significantly reduces the mortality compared to the placebo (OR 0.70, 95% CI 0.58-0.84, p </= 0.001; I (2) = 16.6). Conclusions and Relevance: The result of contemporary meta-analysis suggests mortality benefit with Remdesivir in COVID-19 and median recovery time was over 2 weeks. The pooled mortality with Remdesivir was found to be very low, and this analysis can shed light on this potential treatment for COVID-19 patients. Twit Text FOAVip Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis ????Front Med (Lausanne) http://www.kidney.de/pget.php?&tw=1&pmid=33585508 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33585508 #FOAvip English Wikipedia <ref>{{Cite pmid|33585508}}</ref> Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis #MMPMID33585508 Bansal V; Mahapure KS; Bhurwal A; Gupta I; Hassanain S; Makadia J; Madas N; Armaly P; Singh R; Mehra I; O'Horo JC; Kashyap R Front Med (Lausanne) 2020[]; 7 (ä): 606429 PMID33585508show ga Importance/Background: During current public health emergency of COVID-19 pandemic, repurposing of existing antiviral drugs may be an efficient strategy since there is no proven effective treatment. Published literature shows Remdesivir has broad-spectrum antiviral activity against numerous RNA viruses and has been recently recognized as a promising therapy against SARS-CoV-2. Methods: A systematic search was conducted for full length manuscripts published between inception and July 19th, 2020 focussing on efficacy and safety of Remdesivir in COVID-19. The primary outcomes were defined as mortality rate and median days to recovery based on the available pooled data. The secondary outcome was adverse events rate and drug discontinuation rate. Statistical Analysis: All outcomes were performed using Comprehensive Meta-Analysis software package (Bio stat, Englewood, NJ, USA). Results: A total of 1,895 patients from 9 studies were included in this qualitative synthesis. In patients treated with Remdesivir, the mean recovery time was 15.84 days (95% CI 11.68-20, SE 2.12; I (2) = 97.24) and the pooled mortality rate was 11.3% (95% CI 7.9-16%; I (2) = 74.85). However, treatment with Remdesivir was associated with adverse effects (55.3%, 95% CI 31.5-76.9%; I (2) = 97.66) eventually warranting the discontinuation of the drug (17.8%, 95% CI 8.6-33.1%; I (2) = 95.64). The meta-analysis of three clinical trials indicated that administration of Remdesivir significantly reduces the mortality compared to the placebo (OR 0.70, 95% CI 0.58-0.84, p äMortality Benefit of Remdesivir in COVID-19: A Systematic Review and (epmc).pdf DeepDyve Pubget Overpricing